Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
DTIL 
Precision BioSciences Inc (DTIL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/02/2025: DTIL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $32.5
1 Year Target Price $32.5
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -72.17% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 119.40M USD | Price to earnings Ratio - | 1Y Target Price 32.5 |
Price to earnings Ratio - | 1Y Target Price 32.5 | ||
Volume (30-day avg) 4 | Beta 1.09 | 52 Weeks Range 3.61 - 8.82 | Updated Date 12/2/2025 |
52 Weeks Range 3.61 - 8.82 | Updated Date 12/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -8.96 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-03 | When - | Estimate -0.81 | Actual -1.84 |
Profitability
Profit Margin - | Operating Margin (TTM) -158976.92% |
Management Effectiveness
Return on Assets (TTM) -45.34% | Return on Equity (TTM) -205.16% |
Valuation
Trailing PE - | Forward PE 11.78 | Enterprise Value 115208325 | Price to Sales(TTM) 171.05 |
Enterprise Value 115208325 | Price to Sales(TTM) 171.05 | ||
Enterprise Value to Revenue 165.05 | Enterprise Value to EBITDA -0.27 | Shares Outstanding 24071751 | Shares Floating 12568726 |
Shares Outstanding 24071751 | Shares Floating 12568726 | ||
Percent Insiders 5.87 | Percent Institutions 23.64 |
Upturn AI SWOT
Precision BioSciences Inc
Company Overview
History and Background
Precision BioSciences Inc. was founded in 2006, pioneering the development of ARCUS genome editing technology. It has evolved from a technology platform company to a clinical-stage biopharmaceutical company focused on developing allogeneic CAR T therapies and in vivo gene editing therapeutics.
Core Business Areas
- Allogeneic CAR T Cell Therapy: Development of off-the-shelf CAR T cell therapies using ARCUS genome editing to target hematological malignancies and solid tumors.
- In Vivo Gene Editing: Development of gene editing therapeutics for genetic diseases, delivering ARCUS nucleases directly to specific tissues in the body.
- Platform Technology: Continued development and refinement of the ARCUS genome editing platform, offering potential licensing and collaboration opportunities.
Leadership and Structure
The company is led by a team of experienced executives in biotechnology and pharmaceuticals. The organizational structure consists of research and development, clinical operations, manufacturing, and commercial functions.
Top Products and Market Share
Key Offerings
- PBCAR0191: An allogeneic CAR T cell therapy targeting CD19 for relapsed/refractory B-cell lymphomas. Currently in clinical trials. Market share is not yet applicable as it is not yet approved. Competitors include autologous CAR-T therapies such as Kymriah (Novartis) and Yescarta (Kite Pharma/Gilead).
- PBCAR269A: An allogeneic CAR T cell therapy targeting BCMA for multiple myeloma. Currently in clinical trials. Market share is not yet applicable as it is not yet approved. Competitors include autologous CAR-T therapies such as Abecma (BMS) and Carvykti (Legend Biotech/Janssen).
- In Vivo Gene Editing Programs: Early-stage programs targeting genetic liver diseases. Market share is not yet applicable. Competitors include companies developing CRISPR-based gene editing therapies such as Editas Medicine (EDIT) and Intellia Therapeutics (NTLA).
Market Dynamics
Industry Overview
The genome editing and cell therapy fields are rapidly growing, driven by advancements in technology and increasing demand for novel therapies for genetic diseases and cancer. It's competitive and highly regulated.
Positioning
Precision BioSciences is positioned as a leader in allogeneic CAR T cell therapy and in vivo gene editing using its ARCUS technology. Their competitive advantage lies in the specificity and versatility of the ARCUS platform.
Total Addressable Market (TAM)
The TAM for gene editing and cell therapy is estimated to be in the tens of billions of dollars and growing. Precision BioSciences is positioned to capture a significant share of this market through its innovative technologies and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Proprietary ARCUS genome editing platform
- Experienced leadership team
- Strong intellectual property position
- Advancing clinical pipeline
- Allogeneic CAR T approach has advantages over autologous
Weaknesses
- Clinical trial execution risks
- Dependence on ARCUS platform
- Intense competition in the field
- High cash burn rate
- Reliance on strategic partnerships for funding
Opportunities
- Expanding pipeline into new indications
- Strategic partnerships and collaborations
- Licensing ARCUS technology
- Positive clinical trial results
- Potential for breakthrough therapy designations
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other gene editing technologies (e.g., CRISPR)
- Patent disputes
- Financing challenges
Competitors and Market Share
Key Competitors
- CRSP
- NTLA
- EDIT
- BLUE
Competitive Landscape
Precision BioSciences competes with other gene editing and cell therapy companies. Its ARCUS technology offers advantages in specificity and versatility, but it faces competition from CRISPR-based approaches.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by research and development advancements and strategic partnerships.
Future Projections: Analyst estimates project significant growth in revenue and market capitalization as the company's clinical programs advance. (Quantitive data needed to be provided by analyst estimates)
Recent Initiatives: Recent initiatives include strategic partnerships with other companies, expansion of the clinical pipeline, and advancements in ARCUS technology.
Summary
Precision BioSciences is a clinical-stage biopharmaceutical company with a promising allogeneic CAR T cell therapy and in vivo gene editing programs, driven by its ARCUS platform. While the company faces high cash burn rates and intense competition, potential clinical successes and strategic partnerships offer opportunities. They need to demonstrate clinical efficacy and secure adequate funding to advance programs. The company needs to lookout for competitors and their funding challenges
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (Example)
- Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. The data is based on publicly available information and may not be entirely accurate or complete. Market share data is based on estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Precision BioSciences Inc
Exchange NASDAQ | Headquaters Durham, NC, United States | ||
IPO Launch date 2019-03-28 | President, CEO & Director Mr. Michael Amoroso | ||
Sector Healthcare | Industry Biotechnology | Full time employees 67 | Website https://precisionbiosciences.com |
Full time employees 67 | Website https://precisionbiosciences.com | ||
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-3243 for the treatment of m.3243 associated mitochondrial myopathy. In addition, the company develops PBGENE-NVS (insertion) for sickle cell and beta thalassemia diseases; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LIVER (insertion), a liver directed target; PBGENE-CNS (excision), a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with Novartis Pharma AG to discover and develop in vivo gene editing products; TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; and iECURE, Inc. to develop ARCUS-based gene-insertion therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.